KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $0.1.

  • AbbVie's EPS (Weighted Average and Diluted) fell 8863.64% to $0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.32, marking a year-over-year decrease of 5416.67%. This contributed to the annual value of $2.42 for FY2024, which is 1112.6% down from last year.
  • Per AbbVie's latest filing, its EPS (Weighted Average and Diluted) stood at $0.1 for Q3 2025, which was down 8863.64% from $0.53 recorded in Q2 2025.
  • Over the past 5 years, AbbVie's EPS (Weighted Average and Diluted) peaked at $2.51 during Q1 2022, and registered a low of -$0.01 during Q4 2024.
  • In the last 5 years, AbbVie's EPS (Weighted Average and Diluted) had a median value of $0.77 in 2024 and averaged $1.03.
  • As far as peak fluctuations go, AbbVie's EPS (Weighted Average and Diluted) surged by 2230155.25% in 2021, and later crashed by 10279.13% in 2024.
  • Quarter analysis of 5 years shows AbbVie's EPS (Weighted Average and Diluted) stood at $2.28 in 2021, then tumbled by 38.92% to $1.39 in 2022, then plummeted by 66.57% to $0.46 in 2023, then crashed by 102.79% to -$0.01 in 2024, then soared by 870.87% to $0.1 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.1 in Q3 2025, compared to $0.53 in Q2 2025 and $0.72 in Q1 2025.